The decision follows clinical data from the Phase 3 BREAKWATER trial, which evaluated the efficacy of the regimen against standard oxaliplatin-based chemotherapy. Patients receiving the new combination therapy experienced a median progression-free survival of 12.8 months, compared to 7.1 months for those on traditional chemotherapy. The trial also recorded a significant objective response rate of 60.9% in the primary analysis set, outperforming the 40% response rate observed in the control group.

Eric Ducournau, CEO of Laboratoires Pierre Fabre, noted that the approval addresses a critical gap in clinical options for a patient population that has historically faced limited choices. By integrating encorafenib with cetuximab and chemotherapy, clinicians now have a targeted approach to manage previously untreated BRAFV600E-mutant metastatic colorectal cancer across Europe.